Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA−tcdB+C. difficile prevalent area

Enzyme immunoassays for TcdA and/or TcdB are widely used for diagnosis of C. difficile infection. This study compared the performance of the new VIDAS C. difficile Toxin A & B assay (CDAB) with that of the existing VIDAS C. difficile Toxin A II assay (CDA) in a tcdA−tcdB+ prevalent area. A total of 555 fecal samples were cultured and tested using CDAB and CDA. C. difficile was isolated in 150 samples and the concordance rate was 81.8% (454/555) between CDAB and CDA. PCR assays for tcdA and/or tcdB were used as a confirmatory test on C. difficile strains recovered from culture positive cases (n = 150) and on fecal specimens in culture negative/CDAB positive or equivocal cases (n = 27). The number of tcdA+tcdB+, tcdA−tcdB+, and tcdA−tcdB− strains on culture positive isolates (n = 150) were 75 (50.0%), 41 (27.3%), and 34 (22.7%), respectively. PCR assays for tcdB gene alone in stool specimens (n = 27) showed positivity in five cases. The sensitivity of VIDAS CDAB was higher than that of VIDAS CDA (65.3% vs. 29.8%), by more than 2-fold. The specificity of CDAB was almost the same as CDA (93.8% vs. 94.5%). Toxigenic culture of C. difficile isolates in culture positive/VIDAS CDAB negative cases (n = 62) additionally detected 22 VIDAS CDAB positive and 9 VIDAS CDAB equivocal cases. The VIDAS CDAB assay detects more tcdA+tcdB+ strains (60% vs. 45.3%) and tcdA−tcdB+ strains (70.7% vs. 0%) compared with VIDAS CDA.